

**Ref: 94/SE/LC/2024-25**

**Date: 12/02/2025**

To,  
**Head, Listing Compliance Department  
BSE Limited**  
Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Head, Listing Compliance Department  
National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

**Scrip Code: 544122**

**Scrip Symbol: ENTERO**

Dear Sir/Madam,

**Subject: Submission of Unaudited Financial Results for Quarter and Nine Months ended on December 31, 2024.**

**Reference: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("LODR")**

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today i.e., February 12, 2025, inter alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024 and Limited Review Report on the aforesaid Unaudited Financial Results.

The said results in the prescribed format along with Limited Review Report of Statutory Auditors of the Company are enclosed herewith.

The aforesaid Unaudited Financial Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

The Board Meeting commenced at 2:00 PM (IST) and concluded at 4:15 PM (IST).

This outcome and results will also be uploaded on the website of the Company.

You are requested to take the same on record.

For **Entero Healthcare Solutions Limited**

Sanu Kapoor  
**Vice President- General Counsel, Company Secretary  
& Compliance Officer**



Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN: L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

Statement of Unaudited Standalone Financial Results for the quarter and nine months ended 31 December 2024

Sr. No.	Particulars	(Rs. in Millions, except per equity share data)					
		Quarter ended			Nine Months ended		Year ended
		31 December 24 (Unaudited)	30 September 24 (Unaudited)	31 December 23 (Unaudited)	31 December 24 (Unaudited)	31 December 23 (Unaudited)	31 March 2024 (Audited)
<b>1</b>	<b>Income</b>						
	a) Revenue from operations	1,011.52	1,128.32	765.86	3,363.68	2,116.00	3,181.61
	b) Other income	275.10	288.14	162.50	884.95	475.30	899.25
	<b>Total Income</b>	<b>1,286.62</b>	<b>1,416.46</b>	<b>928.36</b>	<b>4,248.63</b>	<b>2,591.30</b>	<b>4,080.86</b>
<b>2</b>	<b>Expenses</b>						
	a) Purchase of Stock-in-trade	1,287.70	1,001.07	743.42	3,562.12	1,904.21	2,885.03
	b) Changes in inventories of Stock-in-trade	(379.72)	(7.86)	(114.48)	(615.45)	(145.84)	(189.65)
	c) Employee benefits expense	120.44	129.50	149.52	364.83	432.57	562.46
	d) Finance costs	3.70	3.91	47.34	11.71	167.08	223.18
	e) Depreciation and amortisation expense	21.88	21.29	23.20	64.86	70.22	87.48
	f) Other expenses	87.92	86.36	72.38	236.24	178.10	268.71
	<b>Total Expenses</b>	<b>1,141.92</b>	<b>1,214.27</b>	<b>921.38</b>	<b>3,624.31</b>	<b>2,606.34</b>	<b>3,837.21</b>
<b>3</b>	<b>Profit/(Loss) before tax (1) - (2)</b>	<b>144.70</b>	<b>202.19</b>	<b>6.98</b>	<b>624.32</b>	<b>(15.04)</b>	<b>243.65</b>
<b>4</b>	<b>Tax expenses</b>						
	Current tax	6.22	19.72	-	64.16	-	-
	Deferred tax charge/(credit)	30.65	29.18	(2.49)	90.29	(26.65)	(140.75)
	<b>Total tax expenses</b>	<b>36.87</b>	<b>48.90</b>	<b>(2.49)</b>	<b>154.45</b>	<b>(26.65)</b>	<b>(140.75)</b>
<b>5</b>	<b>Profit/(loss) for the period/year (3) -(4)</b>	<b>107.83</b>	<b>153.29</b>	<b>9.47</b>	<b>469.87</b>	<b>11.61</b>	<b>384.40</b>
<b>6</b>	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit and loss	(0.28)	(0.98)	(0.70)	(0.91)	-	1.40
	Income tax effect on above	0.07	0.25	-	0.23	-	(0.35)
	<b>Total other comprehensive income</b>	<b>(0.21)</b>	<b>(0.73)</b>	<b>(0.70)</b>	<b>(0.68)</b>	<b>-</b>	<b>1.05</b>
<b>7</b>	<b>Total comprehensive income (5) + (6)</b>	<b>107.62</b>	<b>152.56</b>	<b>8.77</b>	<b>469.19</b>	<b>11.61</b>	<b>385.45</b>
<b>8</b>	<b>Paid-up equity share capital (face value - Rs. 10 per share)</b>	<b>434.94</b>	<b>434.94</b>	<b>160.67</b>	<b>434.94</b>	<b>160.67</b>	<b>434.94</b>
<b>9</b>	<b>Other equity</b>						<b>15,829.19</b>
<b>10</b>	<b>Earnings per share (Face value of Rs. 10 each) basic- (Rs.)*</b>	<b>2.48</b>	<b>3.52</b>	<b>0.27</b>	<b>10.80</b>	<b>0.33</b>	<b>10.63</b>
	<b>Earnings per share (Face value of Rs. 10 each) diluted - (Rs.)*</b>	<b>2.48</b>	<b>3.52</b>	<b>0.27</b>	<b>10.79</b>	<b>0.33</b>	<b>10.63</b>

(\*not annualised for the quarter and nine months)

See accompanying notes to the audited standalone financial results





**Entero Healthcare Solutions Limited**  
(formerly known as Entero Healthcare Solutions Private Limited)  
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003  
Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051  
CIN:L74999HR2018PLC072204  
Tel. No.: 022-26529100  
Email: info@enterohealthcare.com  
Website: www.enterohealthcare.com

**NOTES:**

- The unaudited standalone financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016, as amended. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited standalone financial results of Entero Healthcare Solutions Limited ("the Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 12 February 2025. These unaudited standalone financial results have been subjected to limited review by the statutory auditors of the Company and they have expressed an unmodified conclusion on these unaudited standalone financial results.
- The Company operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Company has only one reportable segment as per Ind AS 108 "Operating Segments".
- The utilization of the proceeds (net of IPO expenses) as on 31 December 2024 is summarized as below:

Particulars	Utilisation as per prospectus	(Rs. in Millions)	
		Utilisation up to 31 December 2024	Unutilised up to 31 December 2024
Repayment/prepayment in full or part, of certain borrowings availed of by our company	1,425.00	1,425.00	-
Funding of long term working capital requirements of the company and its subsidiaries	4,800.00	3,299.50	1,500.50
Inorganic growth initiative through acquisitions	2,370.00	1,930.00	440.00
General corporate purposes	918.30	491.80	426.50
<b>Total</b>	<b>9,513.30</b>	<b>7,146.30</b>	<b>2,367.00</b>

- During the period ended 31 December 2024, the Company has entered into share purchase agreements with the following entities, resulting in these entities becoming the subsidiary of the Company.

Name of the entity	Date of share transfer	Number of shares acquired	% of shareholding
Avenir Lifecare Pharma Private Limited	07-May-24	8,000	80.0%
Suprabhat Pharmaceutical Distributors Private Limited	12-Jun-24	10,000	100.0%
Devi Pharma Wellness Private Limited	14-Jul-24	10,000	100.0%
Gourav Medical Agencies Private Limited	09-Aug-24	8,000	80.0%
Srinivasa Lifecare Private Limited	13-Aug-24	7,000	70.0%
Peerless Biotech Private Limited	16-Aug-24	30,000	60.0%
Sai Pharma Distributors Private Limited	16-Aug-24	6,93,000	70.0%
Ujjain Maheshwari Pharma Distributors Private Limited	29-Oct-24	10,000	100.0%

- The Company has decided to wind up its three non-operating subsidiaries i.e. Quomed Lifesciences Private Limited, Rimedio Pharma Private Limited and Zenx Software Solutions Private Limited. The Company is in the process of filing with the Registrar of Companies (ROC) to strike off these companies. Other expenses for the quarter and nine months ended December 2024 include Rs. 0.30 million towards impairment of investment in these subsidiaries.
- During the quarter ended December 31, 2024, the Company has issued 75,600 employee stock options under Entero Employee Stock Option Plan 2023.
- The above unaudited standalone financial results of the Company are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE (www.bseindia.com).
- Previous year's/period's figures have been regrouped/reclassified wherever necessary to conform to current period's classification.

Entero Healthcare Solutions Limited

  
Prabhath Agrawat  
CEO & Managing Director  
DIN: 07466382  
Place: Mumbai  
Date: 12 February 2025





**Independent Auditor's Review Report on Standalone unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**To The Board of Directors of Entero Healthcare Solutions Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) (hereinafter referred to as 'the Company') for the quarter ended December 31, 2024 and for the period from April 1, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





# MSKA & Associates

Chartered Accountants

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates  
Chartered Accountants  
ICAI Firm Registration No.105047W



Amrish Vaidya  
Partner  
Membership No.: 101739  
UDIN: 25101739BBIKDJ3906

Place: Mumbai  
Date: February 12, 2025



**Entero Healthcare Solutions Limited**  
(formerly known as Entero Healthcare Solutions Private Limited)  
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003  
Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051  
CIN: L74999HR2016PLC072204  
Tel. No.: 022-26529100  
Email: info@enterohealthcare.com  
Website: www.enterohealthcare.com

**Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended 31 December 2024**

		(Rs. in Millions, except per equity share data)					
Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31 December 24 (Unaudited)	30 September 24 (Unaudited)	31 December 23 (Unaudited)	31 December 24 (Unaudited)	31 December 23 (Unaudited)	31 March 2024 (Audited)
<b>1</b>	<b>Income</b>						
	a) Revenue from operations	13,589.96	13,006.92	9,926.33	37,567.24	28,881.34	39,223.10
	b) Other income	74.98	112.79	17.89	322.13	52.64	144.13
	<b>Total Income</b>	<b>13,664.94</b>	<b>13,119.71</b>	<b>9,944.22</b>	<b>37,889.37</b>	<b>28,933.98</b>	<b>39,367.23</b>
<b>2</b>	<b>Expenses</b>						
	a) Purchase of Stock-in-trade	12,835.33	11,983.59	9,117.36	35,515.64	26,717.66	36,278.08
	b) Changes in inventories of Stock-in-trade	(579.41)	(198.32)	(92.94)	(1,503.77)	(429.80)	(574.55)
	c) Employee benefits expense	533.93	500.66	398.85	1,470.26	1,132.11	1,511.46
	d) Finance costs	99.72	114.58	160.71	311.34	483.61	656.84
	e) Depreciation and amortisation expense	80.99	74.94	59.94	221.98	178.73	250.17
	f) Other expenses	299.99	296.50	217.07	858.78	631.72	889.68
	<b>Total Expenses</b>	<b>13,270.55</b>	<b>12,771.95</b>	<b>9,860.99</b>	<b>36,874.23</b>	<b>28,714.03</b>	<b>39,011.68</b>
<b>3</b>	<b>Profit before tax (1) - (2)</b>	<b>394.39</b>	<b>347.76</b>	<b>83.23</b>	<b>1,015.14</b>	<b>219.95</b>	<b>355.55</b>
<b>4</b>	<b>Tax expenses</b>						
	Current tax (including tax expense of earlier year)	83.29	72.59	15.56	217.44	82.50	133.78
	Deferred tax charge/(credit)	16.62	14.84	(2.14)	37.59	(48.78)	(176.22)
	<b>Total tax expenses</b>	<b>99.91</b>	<b>87.43</b>	<b>13.42</b>	<b>255.03</b>	<b>33.72</b>	<b>(42.44)</b>
<b>5</b>	<b>Profit for the period/year (3) - (4)</b>	<b>294.48</b>	<b>260.33</b>	<b>69.81</b>	<b>760.11</b>	<b>186.23</b>	<b>397.99</b>
<b>6</b>	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit and loss	(0.08)	(0.43)	(1.05)	(0.97)	(0.48)	(2.58)
	Income tax effect on above	0.02	0.11	-	0.24	-	0.41
	<b>Total other comprehensive income</b>	<b>(0.06)</b>	<b>(0.32)</b>	<b>(1.05)</b>	<b>(0.73)</b>	<b>(0.48)</b>	<b>(2.17)</b>
<b>7</b>	<b>Total comprehensive income (5) + (6)</b>	<b>294.42</b>	<b>260.01</b>	<b>68.76</b>	<b>759.38</b>	<b>185.75</b>	<b>395.82</b>
<b>8</b>	<b>Profit attributable to:</b>						
	Owners of the Company	254.38	236.15	67.77	691.33	181.42	391.09
	Non-controlling interests	40.10	24.18	2.04	68.78	4.81	6.90
<b>9</b>	<b>Other comprehensive income attributable to:</b>						
	Owners of the Company	(0.05)	(0.32)	(1.03)	(0.72)	(0.48)	(2.17)
	Non-controlling interests	(0.01)	0.00	(0.02)	(0.01)	-	(0.00)
<b>10</b>	<b>Total comprehensive income attributable to:</b>						
	Owners of the Company	254.33	235.83	66.74	690.61	180.94	388.92
	Non-controlling interests	40.09	24.18	2.02	68.77	4.81	6.90
<b>11</b>	Paid-up equity share capital (face value - Rs. 10 per share)	434.94	434.94	160.67	434.94	160.67	434.94
<b>12</b>	Other equity						15,945.62
<b>13</b>	Earnings per share (Face value of Rs.10 each) basic- (Rs.)*	5.85	5.43	1.91	15.90	5.18	10.81
	Earnings per share (Face value of Rs.10 each) diluted - (Rs.)*	5.84	5.42	1.91	15.87	5.18	10.81

(\*not annualised for the quarter and nine months)

See accompanying notes to the unaudited consolidated financial results





**Entero Healthcare Solutions Limited**  
(formerly known as Entero Healthcare Solutions Private Limited)  
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003  
Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurta Complex, Mumbai - 400051  
CIN: L74999HR2018PLC072204  
Tel. No.: 022-26529100  
Email: info@enterohealthcare.com  
Website: www.enterohealthcare.com

**NOTES:**

- The unaudited consolidated financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016, as amended. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited consolidated financial results of Entero Healthcare Solutions Limited ("the Holding Company" or "the Company"), and its subsidiaries (the Holding Company along with subsidiaries together referred to as "the Group") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 12 February 2025. These unaudited consolidated financial results have been subjected to limited review by the statutory auditors of the Company and they have expressed an unmodified conclusion on these unaudited consolidated financial results.
- The Group operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Group has only one reportable segment as per Ind AS 108 "Operating Segments".
- The utilization of the proceeds (net of IPO expenses) as on 31 December 2024 is summarized as below:


Particulars	Utilisation as per prospectus	(Rs. In Millions)	
		Utilisation up to 31 December 2024	Unutilised up to 31 December 2024
Repayment/prepayment in full or part, of certain borrowings availed by Company	1,425.00	1,425.00	-
Funding of long term working capital requirements of the Company and its subsidiaries	4,800.00	3,299.50	1,500.50
Inorganic growth initiative through acquisitions	2,370.00	1,930.00	440.00
General corporate purposes	918.30	491.80	426.50
<b>Total</b>	<b>9,513.30</b>	<b>7,146.30</b>	<b>2,367.00</b>

- During the quarter ended 30 September 2024, Chhabra Healthcare Solutions Private Limited, a subsidiary of the Company, entered into a business transfer agreement with Amar Drugs Distributors for acquisition of 100% business undertaking on slump sale basis on 9 September 2024. The Company has accounted this acquisition as per Ind AS 103- 'Business Combinations', on provisional basis in the consolidated financial results. The figures for the quarter and nine months ended 31 December 2024 include figures of the aforesaid acquired entity from the date of agreement, and are not comparable with the corresponding/ comparative period.
- During the quarter ended 31 December 2024, Devi Pharma Wellness Private Limited, a subsidiary of the Company, entered into a business transfer agreement with M/s Shree Enterprises for acquisition of 100% business undertaking on slump sale basis on 5 December 2024. The Company has accounted this acquisition as per Ind AS 103- 'Business Combinations', on provisional basis in the consolidated financial results. The figures for the quarter and nine months ended 31 December 2024 include figures of the aforesaid acquired entity from the date of agreement, and are not comparable with the corresponding/ comparative period.
- During the period ended 31 December 2024, the Company has entered into share purchase agreements with the following entities, resulting in these entities becoming the subsidiary of the Company. The Company has accounted these acquisitions as per Ind AS 103- 'Business Combinations', on provisional basis in the unaudited consolidated financial results. The figures for the quarter and nine months ended 31 December 2024 include figures of the aforesaid acquired entities from the date of share transfer as mentioned below, and are not comparable with the corresponding/ comparative period.

Name of the entity	Date of share transfer	Number of shares acquired	% of shareholding
Avenir Lifecare Pharma Private Limited	07-May-24	8,000	80.0%
Suprabhat Pharmaceutical Distributors Private Limited	12-Jun-24	10,000	100.0%
Devi Pharma Wellness Private Limited	14-Jul-24	10,000	100.0%
Gourav Medical Agencies Private Limited	09-Aug-24	8,000	80.0%
Srinivasa Lifecare Private Limited	13-Aug-24	7,000	70.0%
Peerless Biotech Private Limited	16-Aug-24	30,000	60.0%
Sai Pharma Distributors Private Limited	16-Aug-24	6,93,000	70.0%
Ujain Maheshwari Pharma Distributors Private Limited	29-Oct-24	10,000	100.0%

- During the quarter ended December 31, 2024, the Company has issued 75,600 employee stock options under Entero Employee Stock Option Plan 2023.
- The above unaudited consolidated financial results of the Group are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE(www.bseindia.com).
- Previous year's/period's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's classification.

Entero Healthcare Solutions Limited

  
Prabhat Agrawal  
CEO & Managing Director  
DIN: 07466382  
Place: Mumbai  
Date: 12 February 2025





**Independent Auditor's Review Report on consolidated unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

## **To the Board of Directors of Entero Healthcare Solutions Limited**

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2024 and for the period from April 1, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the entities listed in Annexure A
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. We did not review the interim financial information of 8 subsidiaries included in the Statement, whose interim financial information (before consolidation adjustments) reflects total revenues of Rs. 2,901.46 million and Rs. 6,713.26 million, total net profit after tax (net) of Rs. 106.75 million and Rs. 159.39 million and total comprehensive income (net) of Rs. 106.75 million and Rs.159.15 million, for the quarter ended December 31, 2024 and for the period from April 1, 2024 to December 31, 2024, respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and reports of the other auditors.

7. The Statement includes the interim financial information of 21 subsidiaries which have not been reviewed by their auditors and are not subject to review, whose interim financial information (before consolidation adjustments) reflects total revenue of Rs. 1,705.38 million and Rs. 4,123.98 million, total net profit/(loss) after tax (net) of Rs.5.21 million and Rs.(20.33) million and total comprehensive income / (loss) (net) of Rs. 5.21 million and Rs. (20.61) million for the quarter ended December 31, 2024 and for the period from April 1, 2024 to December 31, 2024, respectively, as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such Management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial information certified by the Management.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Amrish Vaidya

Partner

Membership No.: 101739

UDIN: 25101739BMIKDK7149

Place: Mumbai

Date: February 12, 2025



Annexure A to the Independent Auditor's Review Report on consolidated unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to date pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Novacare Healthcare Solutions Private Limited	Subsidiary
2	R S M Pharma Private Limited	Subsidiary
3	Avenues Pharma Distributors Private Limited	Subsidiary
4	Chirag Medicare Solutions Private Limited	Subsidiary
5	Chethana Pharma Private Limited	Subsidiary
6	Jaggi Enterprises Private Limited	Subsidiary
7	Vasavi Medicare Solutions Private Limited	Subsidiary
8	SVMED Solutions Private Limited	Subsidiary
9	Millennium Medisolutions Private Limited	Subsidiary
10	G.S. Pharmaceutical Distributors Private Limited	Subsidiary
11	Getwell Medicare Solution Private Limited	Subsidiary
12	Galaxystar Pharma Distributors Private Limited	Subsidiary
13	Barros Enterprises Private Limited	Subsidiary
14	Sesha Balajee Medisolutions Private Limited	Subsidiary
15	Rada Medisolutions Private Limited	Subsidiary
16	Sri Parshva Pharma Distributors Private Limited	Subsidiary
17	Sri Rama Pharmaceutical Distributors Private Limited	Subsidiary
18	Western Healthcare Solutions Private Limited	Subsidiary
19	Chhabra Healthcare Solutions Private Limited	Subsidiary
20	Chethana Healthcare Solutions Private Limited	Subsidiary
21	S.S. Pharma Traders Private Limited	Subsidiary
22	Sundarlal Pharma Distributors Private Limited	Subsidiary
23	New Siva Agencies Private Limited	Subsidiary
24	Saurashtra Medisolutions Private Limited	Subsidiary
25	New RRPD Private Limited	Subsidiary
26	Sree Venkateshwara Medisolutions Private Limited	Subsidiary
27	SVS Lifesciences Private Limited	Subsidiary
28	Swami Medisolutions Private Limited	Subsidiary
29	Atreja Healthcare Solutions Private Limited	Subsidiary
30	CPD Pharma Private Limited	Subsidiary
31	Calcutta Medisolutions Private Limited	Subsidiary
32	Chethana Pharma Distributors Private Limited	Subsidiary
33	City Pharma Distributors Private Limited	Subsidiary
34	Curever Pharma Private Limited	Subsidiary
35	Rimedio Pharma Private Limited	Subsidiary
36	Quromed Life Sciences Private Limited	Subsidiary
37	Zennx Software Solutions Private Limited	Subsidiary
38	Entero R.S. Enterprises Private Limited	Subsidiary
39	Dhanvanthri Super Specialty Private Limited	Subsidiary





# MSKA & Associates

Chartered Accountants

40	Avenir Lifecare Pharma Private Limited (w.e.f. May 7, 2024)	Subsidiary
41	Suprabhat Pharmaceuticals Private Limited (w.e.f. June 12, 2024)	Subsidiary
42	Devi Pharma Wellness Private Limited (w.e.f. July 14, 2024)	Subsidiary
43	Gourav Medical Agencies Private Limited (w.e.f. August 9, 2024)	Subsidiary
44	Srinivasa Lifecare Private Limited (w.e.f. August 13, 2024)	Subsidiary
45	Sai Pharma Distributor Private Limited (w.e.f. August 16, 2024)	Subsidiary
46	Peerless Biotech Private Limited (w.e.f. August 16, 2024)	Subsidiary
47	Ujjain Maheshwari Pharma Distributor Private Limited (w.e.f. October 29, 2024)	Subsidiary

